Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/49503
Title: Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate.
Author: Kluge, Michael
Hegerl, Ulrich
Sander, Christian
Dietzel, Jens
Mergl, Ronald
Bitter, Istvan
Demyttenaere, Koen
Gusmão, Ricardo
Gonzalez Pinto, Ana
Perez-Sola, Victor
Vieta i Pascual, Eduard, 1963-
Juckel, Georg
Zimmermann, Ulrich S.
Bauer, Michael
Sienaert, Pascal
Quintao, Sónia
Edel, Marc-Andreas
Bolyos, Csilla
Ayuso Mateos, Jose Luis
López García, Pilar
Keywords: Trastorn bipolar
Antidepressius
Assaigs clínics de medicaments
Manic-depressive illness
Antidepressants
Drug testing
Issue Date: 27-Feb-2013
Publisher: BioMed Central
Abstract: BACKGROUND: Treatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the 'vigilance regulation model of mania' which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania. METHODS/DESIGN: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression-Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-'Vigilance Algorithm Leipzig' (VIGALL). DISCUSSION: A positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-244X-13-71
It is part of: BMC Psychiatry, 2013, vol. 13, num. 13, p. 71
Related resource: http://dx.doi.org/10.1186/1471-244X-13-71
URI: http://hdl.handle.net/2445/49503
ISSN: 1471-244X
Appears in Collections:Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Files in This Item:
File Description SizeFormat 
626864.pdf344.44 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons